NCT05996367 is a NA clinical trial of Single-dose involved-site radiotherapy in Multiple Myeloma, sponsored by Instituto do Cancer do Estado de São Paulo.

Who is sponsoring NCT05996367?

NCT05996367 is sponsored by Instituto do Cancer do Estado de São Paulo.

What drugs are being tested in NCT05996367?

Interventions in NCT05996367: Single-dose involved-site radiotherapy.

What condition does NCT05996367 study?

NCT05996367 studies Multiple Myeloma.

Is NCT05996367 still recruiting?

NCT05996367 is currently recruiting now. Last updated 18 August 2023.

Last reviewed 2023-08-18 · How we verify

NCT05996367

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma

Recruiting now NA Last updated 18 August 2023

What this trial tests

NA trial testing Single-dose involved-site radiotherapy in Multiple Myeloma in 50 participants. Currently enrolling.

Timeline

31 July 2023

Primary endpoint
31 July 2028

31 July 2029

Quick facts

Lead sponsor	Instituto do Cancer do Estado de São Paulo
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	31 July 2023
Primary completion	31 July 2028
Estimated completion	31 July 2029
Sites	1 location across Brazil

Drugs / interventions tested

Single-dose involved-site radiotherapy

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Instituto do Cancer do Estado de São Paulo — full company profile →

Who can join

Adults 18 to 85, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple myeloma is a plasma cell neoplasm that can cause painful bone lesions. The main treatment for these lesions and pain control is radiotherapy, usually in daily fractions. In 2017, a phase III study proved the effectiveness of using a single dose of 8 Gy, but without description of several important oncological outcomes. This is a single-arm prospective cohort study. This study aims to describe these outcomes, including retreatment rate and bone events. Also, as secondary objectives, describe the quality of life and use of analgesic medications in this population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Instituto do Cancer do Estado de São Paulo trials

Trials by the same sponsor.

NCT06887621 — Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk f · Phase 2 · recruiting
NCT07066046 — Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions · NA · recruiting
NCT06282354 — Telemedicine for Postoperative Follow-up After Oncological Surgeries · unknown
NCT05622136 — Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma · Phase 2 · active not recruiting
NCT06070376 — Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05996367 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto do Cancer do Estado de São Paulo
Last refreshed: 18 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05996367.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing